VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,570,537 | +2.0% | 70,038 | -0.0% | 0.01% | +10.0% |
Q2 2023 | $3,498,896 | +75.4% | 70,062 | +31.6% | 0.01% | +66.7% |
Q1 2023 | $1,994,723 | -20.1% | 53,221 | +2.2% | 0.01% | -25.0% |
Q4 2022 | $2,497,524 | -56.2% | 52,086 | -78.1% | 0.01% | -55.6% |
Q3 2022 | $5,698,000 | +44.2% | 237,433 | +30.8% | 0.02% | +80.0% |
Q2 2022 | $3,951,000 | -21.1% | 181,589 | -12.4% | 0.01% | 0.0% |
Q1 2022 | $5,005,000 | +1.5% | 207,240 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $4,930,000 | +15.5% | 207,240 | +23.2% | 0.01% | +11.1% |
Q3 2021 | $4,269,000 | +47.4% | 168,280 | +30.8% | 0.01% | +50.0% |
Q2 2021 | $2,896,000 | +41.6% | 128,675 | +24.3% | 0.01% | +50.0% |
Q1 2021 | $2,045,000 | +19.2% | 103,520 | +60.3% | 0.00% | 0.0% |
Q4 2020 | $1,715,000 | +20.6% | 64,560 | +124.2% | 0.00% | 0.0% |
Q3 2020 | $1,422,000 | – | 28,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,457,300 | $54,619,604 | 23.40% |
Pivotal bioVenture Partners Investment Advisor LLC | 693,039 | $25,975,102 | 10.70% |
RA Capital Management | 7,291,254 | $273,276,200 | 6.19% |
Kynam Capital Management, LP | 1,216,784 | $45,605,064 | 5.89% |
GREAT POINT PARTNERS LLC | 659,211 | $24,707,228 | 4.85% |
Frazier Life Sciences Management, L.P. | 1,397,405 | $52,374,739 | 3.79% |
ACUTA CAPITAL PARTNERS, LLC | 120,500 | $4,516,340 | 3.33% |
Ghost Tree Capital, LLC | 225,000 | $8,433,000 | 2.49% |
Carlyle Group Inc. | 1,923,158 | $72,079,962 | 2.15% |
Opaleye Management Inc. | 177,000 | $6,633,960 | 1.99% |